Eli Lilly's weight-loss drug could generate billions in sales

investors.com

Eli Lilly's new weight-loss drug could generate over $62 billion in 2030 sales, with a potential increase to $81 billion when factoring in next-generation drugs. Analyst Geoff Meacham raised the stock's price target to 1,000, citing a competitive advantage over rivals. Eli Lilly and Novo Nordisk lead the obesity treatment space, with a projected 7% of U.S. adults using GLP-1 agonist drugs for weight loss by 2030. The stock has a 29% year-to-date increase and a Relative Strength Rating of 95.


With a significance score of 3.8, this news ranks in the top 6.4% of today's 29067 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Eli Lilly's weight-loss drug could generate billions in sales | News Minimalist